CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Pliant Therapeutics, Inc. - PLRX CFD

12.56
6.17%
Market Trading Hours* (UTC) Opens on Wednesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.09
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026235 %
Charges from full value of position ($-0.26)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004012 %
Charges from full value of position ($0.04)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.004012%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 11.83
Open 12.51
1-Year Change -21.71%
Day's Range 12.15 - 12.8
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 17, 2024 12.56 0.59 4.93% 11.97 12.87 11.97
Sep 16, 2024 11.83 -0.43 -3.51% 12.26 12.26 11.49
Sep 13, 2024 11.95 0.14 1.19% 11.81 12.00 11.62
Sep 12, 2024 11.79 -0.43 -3.52% 12.22 12.31 11.73
Sep 11, 2024 12.21 -0.34 -2.71% 12.55 12.71 12.19
Sep 10, 2024 12.94 0.06 0.47% 12.88 13.07 12.61
Sep 9, 2024 12.84 -0.09 -0.70% 12.93 13.51 12.74
Sep 6, 2024 12.84 -0.30 -2.28% 13.14 13.45 12.52
Sep 5, 2024 13.31 0.80 6.39% 12.51 13.43 12.49
Sep 4, 2024 12.78 0.24 1.91% 12.54 12.89 12.38
Sep 3, 2024 12.75 -0.03 -0.23% 12.78 13.48 12.61
Aug 30, 2024 13.25 0.14 1.07% 13.11 13.32 12.84
Aug 29, 2024 13.12 0.48 3.80% 12.64 13.52 12.63
Aug 28, 2024 12.85 -0.03 -0.23% 12.88 13.10 12.68
Aug 27, 2024 13.06 0.04 0.31% 13.02 13.41 12.71
Aug 26, 2024 13.42 -0.03 -0.22% 13.45 13.53 13.26
Aug 23, 2024 13.43 0.23 1.74% 13.20 13.66 12.98
Aug 22, 2024 13.18 0.06 0.46% 13.12 13.65 13.04
Aug 21, 2024 13.39 -0.17 -1.25% 13.56 13.92 13.36
Aug 20, 2024 13.86 0.85 6.53% 13.01 14.03 12.97

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Pliant Therapeutics, Inc. Company profile

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Pliant Therapeutics Inc revenues decreased 82% to $7.6M. Net loss increased from $41.5M to $97.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 14% to $73.6M (expense), General and administrative - Balancing increase of 39% to $21M (expense).

Industry: Pharmaceuticals (NEC)

260 Littlefield Avenue
Suite 150
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

News

Bank of Japan Preview

The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.

09:40, 17 September 2024

FOMC Decision Preview

As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.

09:48, 16 September 2024

ECB Preview: cuts expected but the pace is uncertain

Markets expect the ECB to cut rates again in September, but how many more?

12:34, 11 September 2024

Market analysis: US CPI and PPI

Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.

07:56, 10 September 2024

Introducing Newsquawk: your new in-platform newsfeed

We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.

14:09, 20 August 2024

Jackson Hole Preview: All eyes on Powell and Gold

The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.

15:24, 19 August 2024

All eyes on inflation: US and UK CPI take centre stage

Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.

14:41, 13 August 2024

People also watch

Gold

2,568.36 Price
-0.070% 1D Chg, %
Long position overnight fee -0.0195%
Short position overnight fee 0.0113%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

19,468.90 Price
+0.160% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Oil - Crude

69.59 Price
-0.460% 1D Chg, %
Long position overnight fee 0.0415%
Short position overnight fee -0.0634%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.58 Price
-1.580% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 640,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading